Free Trial

Syndax Pharmaceuticals (SNDX) Competitors

+0.10 (+0.48%)
(As of 05/22/2024 ET)


Should you be buying Syndax Pharmaceuticals stock or one of its competitors? The main competitors of Syndax Pharmaceuticals include NewAmsterdam Pharma (NAMS), Ardelyx (ARDX), Evotec (EVO), Keros Therapeutics (KROS), Kura Oncology (KURA), Harmony Biosciences (HRMY), Edgewise Therapeutics (EWTX), Structure Therapeutics (GPCR), Protagonist Therapeutics (PTGX), and Galapagos (GLPG). These companies are all part of the "pharmaceutical preparations" industry.

Syndax Pharmaceuticals vs.

Syndax Pharmaceuticals (NASDAQ:SNDX) and NewAmsterdam Pharma (NASDAQ:NAMS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, community ranking, media sentiment, profitability, institutional ownership, risk, dividends and earnings.

In the previous week, Syndax Pharmaceuticals had 2 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 8 mentions for Syndax Pharmaceuticals and 6 mentions for NewAmsterdam Pharma. Syndax Pharmaceuticals' average media sentiment score of 0.69 beat NewAmsterdam Pharma's score of 0.14 indicating that Syndax Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Syndax Pharmaceuticals
3 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
NewAmsterdam Pharma
0 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)

Syndax Pharmaceuticals has a beta of 1.01, indicating that its share price is 1% more volatile than the S&P 500. Comparatively, NewAmsterdam Pharma has a beta of 0.08, indicating that its share price is 92% less volatile than the S&P 500.

89.9% of NewAmsterdam Pharma shares are held by institutional investors. 4.1% of Syndax Pharmaceuticals shares are held by insiders. Comparatively, 19.5% of NewAmsterdam Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

NewAmsterdam Pharma's return on equity of 0.00% beat Syndax Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Syndax PharmaceuticalsN/A -53.32% -48.46%
NewAmsterdam Pharma N/A N/A N/A

NewAmsterdam Pharma has lower revenue, but higher earnings than Syndax Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Syndax Pharmaceuticals$139.71M12.63-$209.36M-$3.22-6.45
NewAmsterdam Pharma$6.86M256.74-$176.94MN/AN/A

Syndax Pharmaceuticals presently has a consensus target price of $34.42, suggesting a potential upside of 65.78%. NewAmsterdam Pharma has a consensus target price of $33.25, suggesting a potential upside of 69.82%. Given NewAmsterdam Pharma's stronger consensus rating and higher possible upside, analysts clearly believe NewAmsterdam Pharma is more favorable than Syndax Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Syndax Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
NewAmsterdam Pharma
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)

Syndax Pharmaceuticals received 356 more outperform votes than NewAmsterdam Pharma when rated by MarketBeat users. However, 100.00% of users gave NewAmsterdam Pharma an outperform vote while only 64.79% of users gave Syndax Pharmaceuticals an outperform vote.

Syndax PharmaceuticalsOutperform Votes
Underperform Votes
NewAmsterdam PharmaOutperform Votes
Underperform Votes
No Votes


NewAmsterdam Pharma beats Syndax Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

Get Syndax Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for SNDX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SNDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SNDX vs. The Competition

MetricSyndax PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1.76B$6.64B$5.12B$8.01B
Dividend YieldN/A2.71%2.81%3.91%
P/E Ratio-6.4523.09180.0018.65
Price / Sales12.63189.972,442.6195.81
Price / CashN/A35.9636.0832.25
Price / Book3.595.505.434.62
Net Income-$209.36M$99.33M$105.77M$214.11M
7 Day Performance-0.76%-0.46%-0.65%-0.01%
1 Month Performance-1.00%3.67%3.42%3.96%
1 Year Performance-5.21%-5.71%5.88%8.02%

Syndax Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NewAmsterdam Pharma
2.9519 of 5 stars
4.3181 of 5 stars
+119.7%$1.80B$124.46M-27.57267Analyst Downgrade
1.8389 of 5 stars
N/A$1.80B$791.73M0.004,952News Coverage
High Trading Volume
Keros Therapeutics
1.1967 of 5 stars
Kura Oncology
2.0456 of 5 stars
Harmony Biosciences
4.1189 of 5 stars
-15.3%$1.68B$582.02M12.84246Positive News
Edgewise Therapeutics
1.5476 of 5 stars
+87.6%$1.67BN/A-11.5492Positive News
Structure Therapeutics
1.6904 of 5 stars
+48.7%$1.67BN/A-46.5193Analyst Forecast
News Coverage
Gap Up
Protagonist Therapeutics
1.0341 of 5 stars
0.253 of 5 stars

Related Companies and Tools

This page (NASDAQ:SNDX) was last updated on 5/23/2024 by Staff

From Our Partners